### Research Article

## Chemical Profiling of an Antimigraine Herbal Preparation, Tianshu Capsule, Based on the Combination of HPLC, LC-DAD-MS<sup>n</sup>, and LC-DAD-ESI-IT-TOF/MS Analyses

# Juanjuan Liang,<sup>1,2</sup> Huimin Gao,<sup>1,2</sup> Liangmian Chen,<sup>1,2</sup> Wei Xiao,<sup>3</sup> Zhenzhong Wang,<sup>3</sup> Yongyan Wang,<sup>1</sup> and Zhimin Wang<sup>1,2</sup>

<sup>1</sup> Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China

<sup>2</sup> National Engineering Laboratory for Quality Control Technology of Chinese Herbal Medicine, Beijing 100700, China <sup>3</sup> Jiangsu Kanion Pharmaceut Co. Ltd., Lianyungang 222001, China

Correspondence should be addressed to Huimin Gao; huimin\_gao@126.com and Zhimin Wang; zhmw123@263.net

Received 17 April 2014; Revised 28 June 2014; Accepted 30 June 2014; Published 20 July 2014

Academic Editor: Shi-Biao Wu

Copyright © 2014 Juanjuan Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chemical profiling is always the first task in the standardization and modernization of Traditional Chinese Medicine. HPLC and LC-MS were employed to find out the common chromatographic peaks in various batches of Tianshu Capsule (TSC) and the contribution of the characteristic peaks from individual herbs to the whole chromatographic profile of TSC sample. A total of 38 constituents were identified in TSC sample based on the comparison of retention time and UV spectra with authentic compounds as well as by summarized MS fragmentation rules and matching of empirical molecular formula with those of published components. This is the first systematic report on the chemical profiling of the commercial TSC product, which provides the sufficiently chemical evidence for the global quality evaluation of TSC products.

#### 1. Introduction

Traditional Chinese Medicine (TCM) is getting more attention all over the world due to its exact clinical practice, especially prescription application, which comprehensively highlights the quintessence of the theory of traditional Chinese medical science. Da Chuan Xiong Fang (DCXF), a well-known and extensively used TCM decoction for the treatment of migraine, first appeared in Xuan Ming Lun Fang, a famous formula book written by Wansu Liu who lived in Jin Dynasty (1115–1234). It is composed of two herbs, namely, Chuanxiong (Chuanxiong rhizoma) and Tianma (Gastrodiae *rhizoma*), with a crude weight ratio of 4 : 1. Eight dosage forms of DCXF such as capsule, tablet, dripping-pill, honeyed pill, oral liquid, and granule, have been authorized to Chinese market. Tianshu Capsule (TSC), as a representative of DCXF preparations, is widely used in clinics for treating the blood stasis type of headache and migraine [1, 2].

Phytochemical and pharmacological investigations showed that phenols, organic acids, phthalides, and nitrogen-containing compounds were the major active ingredients of DCXF [3]. Several qualitative analyses have been reported concerning main types of constituents in DCXF [4-7]. One study described the identification of 17 different constituents in the 50% EtOH extract of DCXF by LC-Q-TOF/MS, containing gastrodin, parishin C, ferulic acid, guanosine, adenosine, palmitic acid, and 11 phthalide compounds [4]. Another similar study identified 3 compounds of Chuanxiong (ferulic acid, senkyunolide I, and senkyunolide H) and 8 constituents of Tianma (gastrodin, s-(4-hydroxybenzyl)-glutathione, parishin, parishin B, parishin C, p-hydroxybenzaldehyde, etc.) by using the HPLC-DAD-MS<sup>n</sup> coupling technique, respectively [5]. Continuous reports from the second research group confirmed that 10 different compounds, including 6 original substances of Chuanxiong and 4 original ones of Tianma, were detected in the rat plasma after the gavage of DCXF active components [6, 7]. However, all these investigations mentioned above were carried out based on the samples of the 50% EtOH extract of the mixture of both herbs (4:1) or active components of single crude herb. No systematic reports could be available involving the chemical profiling of the commercial finished products derived from DCXF. TSC was produced from both crude herbs by employing the various pharmaceutical engineering technologies and the complex manufacturing processes such as extraction, concentration, and preparation. The accumulating studies showed that decocting could induce chemical changes of medicinal herbs or combinatorial formula [8]. It is wellknown that ferulic acid and some of the phthalides such as Z-ligustilide and dimeric phthalide are unstable at high temperature [9, 10]. Therefore, during the preparation of TSC, these thermolabile components may undertake chemical transformation, consequently leading to the difference of chemical compositions of finished products with DCXF decoction. Understanding the chemical profiles of TSC samples would be helpful in selecting suitable chemical markers for the quality control and pharmacokinetic study. In this work, a combination of HPLC, LC-DAD-MS<sup>n</sup>, and LC-DAD-ESI-IT-TOF/MS analyses was employed to find out and identify the common components in various batches of commercial TSC samples. The contribution of the characteristic peaks from individual herb to the whole chemical profiling of TSC was also discussed. A total of 38 constituents were identified or tentatively characterized, among which the water-soluble compounds with higher polarity from Gastrodiae rhizoma are detected in TSC samples for the first time.

#### 2. Materials and Methods

2.1. Materials and Reagents. Five batches of Tianshu Capsules and related crude herbal materials (Chuanxiong rhizoma and Gastrodiae rhizoma) were provided by Kanion Pharmaceutical (Lianyungang, China). The reference substances of gastrodin (Lot. 110807-200205), 5-hydroxymethyl-2-furfural (5-HMF, Lot. 111626-201007), ferulic acid (Lot. 0773-9607), and Z-ligustilide (Lot. 111737-201102) were purchased from the National Institutes for Food and Drug Control (Beijing, China). Parishin B (174972-79-3), parishin C (174972-80-6), and parishin (62499-28-9) were from the collection of Dr. Li Wang, Dalian Institute of Chemical Physics, Chinese Academy of Sciences (Dalian, China). The purity for each of these compounds was over 98% by HPLC assay and their structures were shown in Figure 1. HPLC grade methanol (Fisher, Fair Lawn, NJ, USA) and ultrapure water were used for HPLC analyses. All other chemical reagents were of analytical grade from Beijing Chemical Corporation (Beijing, China).

#### 2.2. Sample Preparation

2.2.1. TSC Sample. 1.0 g of pulverized contents of TSC samples was extracted with aqueous methanol (MeOH-H<sub>2</sub>O, 1:1,

25 mL) by ultrasonication (250 w, 40 kHz) for 30 min at room temperature, and the extract was then centrifuged for 10 min at 14800 rpm. A volume of 10  $\mu$ L of the supernatant was used for HPLC and LC-DAD-MS<sup>n</sup> analysis.

2.2.2. Extraction of Chuanxiong Rhizoma, Gastrodiae Rhizoma, and DCXF. The ethanolic and aqueous extracts of individual herb (*Chuanxiong rhizoma* and *Gastrodiae rhizoma*) and the mixture of both herbs (w/w, 4:1, DCXF) were prepared according to the manufacturing processes of TSC (Figure S1 in the Supplementary Material available online at http://dx.doi.org/10.1155/2014/580745) described in the current Chinese pharmacopoeia. The ethanolic and aqueous extracts were diluted with aqueous methanol (MeOH-H<sub>2</sub>O, 1:1) to the concentration of 0.05 g·mL<sup>-1</sup> and then centrifuged for 10 min at 14800 rpm. Each of the supernatants was used for HPLC and LC-MS analyses.

2.2.3. Reference Solution. Stock solutions with a concentration of about  $0.010 \text{ mg} \cdot \text{mL}^{-1}$  were prepared by dissolving an accurately weighed amount of each reference substance in aqueous methanol (MeOH-H<sub>2</sub>O, 1:1). The mixture of 7 reference solutions was prepared from the stock solutions.

2.3. Qualitative HPLC Analyses of 5 Batches of TSC Samples. The analyses were performed on a Shimadzu HPLC system (Shimadzu, Japan) equipped with a LC-20AT binary pump, a DGU-20A5 degasser, a SIL-20AC autosampler, a CTO-20AC column oven, and a SPD-M20A photodiode array detector. The samples were separated on a Phenomenex Luna C<sub>18</sub> column (5  $\mu$ m, 4.6 × 250 mm). The mobile phase consisted of methanol (A) and water containing 0.1% formic acid (B) using a gradient program as follows: 0 min, 15% A; 55 min, 15% A; 55 min, 95% A; 60 min, 95% A. The flow rate was 1.0 mL·min<sup>-1</sup> and the column temperature was set at 30°C. The PDA detector recorded UV spectra in the range from 190 nm to 400 nm and HPLC chromatogram was monitored at 276 nm.

2.4. Comparison of Typical TSC Sample and Its Related Crude Herbal Materials as Well as DCXF by HPLC and LC-MS. TSC sample and its related crude herbal material, Chuanxiong rhizoma and Gastrodiae rhizoma as well as DXCF, were analyzed under the same chromatographic conditions by HPLC and LC-MS to find the contribution of individual herb to the whole chemical profile of TSC sample. The HPLC system was the same as those in Section 2.3. LC-MS analyses were performed using an Agilent 6130 Quadrupole LC-MS (Agilent, Waldbronn, Germany) connected to an Agilent 1200 HPLC system (Agilent, Waldbronn, Germany). The parameters for MS analysis in the positive and negative ion mode were as follows: nebulizer, 35 psi; ionization voltage, 3500 V; dry temperature, 350°C; flow rate of carrier gas, 9.0 L·min<sup>-1</sup>. Full-scan mass spectra were acquired in the range of 100-800 m/z.

2.5. LC-DAD-ESI-IT- $MS^n$  Analysis of Typical TSC Sample. To comprehensively identify the chemical constituents in



FIGURE 1: The structures of the identified compounds in TSC sample.

TSC sample by the fragmentation rules, a LC-DAD-ESI-IT-MS<sup>n</sup> experiment was performed using an Agilent 6320 ion-trap spectrometer (Agilent, Waldbronn, Germany) connected to an Agilent 1200 HPLC system (Agilent, Waldbronn, Germany). The HPLC conditions were the same as those described in Section 2.3. The LC effluent was introduced into an electrospray ionization source after a postcolumn split ratio of 2 : 1. The parameters for MS analysis in the positive ion mode were as follows: nebulizer, 45 psi; ionization voltage, 4000 V; dry temperature, 350°C; flow rate of carrier gas, 12.0 L·min<sup>-1</sup>. Full-scan mass spectra were acquired in the range of 100–800 *m/z*. The optimized parameters for MS/MS analysis were as follows: collision energy, 1.5 V; nitrogen was used as the collision gas. MS<sup>n</sup> spectra of pure substances were obtained using the same parameters as mentioned above.

2.6. LC-DAD-ESI-IT-TOF/MS of Analysis of Typical TSC Sample. To confirm the elemental composition of precursor ions and their fragments with high-accurate mass, a LC-ESI-IT-TOF/MS experiment was performed on a Shimadzu LC-MS-IT-TOF instrument equipped with a Shimadzu UFLCXR HPLC system (Shimadzu, Kyoto, Japan). The HPLC system consisted of a CBM-20A controller, two LC-20AD binary pumps, an SPD-M20A diode array detector, an SIL-20AC autosampler, a CTO-20A column oven, and a DGU-20A3 degasser. The HPLC conditions were the same as those for HPLC-DAD-ESI-MS<sup>n</sup> analysis. The LC effluent was directed into the ESI source as a rough split ratio of 3:1. The optimized MS conditions were as follows: positive and negative ion mode; electrospray voltage, +4.5 kV/-3.5 kV; detector voltage, 1.65 kV; curved desolvation line (CDL) temperature, 200°C; heat block temperature, 200°C; nebulizing gas  $(N_2)$ ,  $1.5 \text{ L·min}^{-1}$ ; drying gas (N<sub>2</sub>),  $10 \text{ L·min}^{-1}$ ; scan range, m/z100-1100 for MS<sup>1</sup>, 100-800 for MS<sup>2</sup>, and 100-500 for MS<sup>3</sup>. The ultrahigh purity argon was used as the collision gas for collision-induced dissociation (CID) experiments, and the collision energy was set at 50% for MS<sup>2</sup> and MS<sup>3</sup>; ion accumulated time was 30 ms. The  $MS^n$  data were collected in an automatic mode and the software could automatically select precursor ions for MS<sup>n</sup> analysis according to criteria settings. Accurate mass determination was corrected using the external standard method. The data acquisition and analysis were performed by LC-MS Solution Version 3.6 software (Shimadzu, Kyoto, Japan).

#### 3. Results and Discussion

3.1. Qualitative Analyses of TSC and Its Related Crude Herbal Materials by HPLC and LC-MS. Under the HPLC conditions as described in the current Chinese Pharmacopoeia [1], 5 batches of TSC samples, together with the reference compounds, were examined and their HPLC chromatograms were shown in Figure S2. High similarity in the number, type, and amount of chemical constituents was observed in the HPLC profiles of different batches of TSC samples. General chromatographic profile was obtained by Similarity Evaluation System for Chromatographic Fingerprint of Traditional Chinese Medicine software and characteristic peaks were found in the HPLC profile of each individual sample.

In order to identify the origin of these characteristic peaks from individual herbs, a comparative study was carried out by using various extracts of herbs and TSC samples. Accordingly, the possible individual contribution from the corresponding herbs to the general chromatographic profile was found. Compared with the HPLC profiles of the ethanolic and aqueous extracts of Chuanxiong rhizoma and Gastrodiae rhizoma (Figure S3), 29 of 38 peaks occurring in HPLC profile of TSC sample were contributed by Chuanxiong rhizoma and other 9 peaks came from Gastrodiae rhizoma (Figures S4  $\sim$  S10). In addition to the comparison of retention time and on-line UV spectra with those of reference compounds gastrodin, 5-HMF, parishin B, parishin C, parishin, ferulic acid, and Z-ligustilide, the precursor ions obtained by the positive and negative LC-MS (Figure 2) such as  $[M+H]^+$ ,  $[M+NH_4]^+$ ,  $[M+Na]^+$ , and  $[M-H]^-$  further confirmed the contribution of the characteristic peaks from individual herbs to the chromatographic profile of TSC sample (Table 1).

3.2. Identification of Chemical Constituents in TSC by LC-DAD-EST-IT-MS<sup>n</sup> and LC-DAD-ESI-IT-TOF/MS. The combination of LC-DAD-ESI-IT-MS<sup>n</sup> and LC-DAD-ESI-IT-TOF/MS experiments was employed for the identification of chemical constituents in TSC sample, and, as a result, a total of 38 compounds was identified or tentatively characterized. The structures of the identified compounds are shown in Figure 1 and their chromatographic and mass spectrometric data are shown in Tables 2 and 3. The total ion chromatograms (TICs) of TSC sample are shown in Figures S11 and S12, respectively. Among the identified constituents, 7 compounds (2, 3, 5, 6, 7, 9, and 26) were unambiguously identified as gastrodin, 5-HMF, parishin B, parishin C, parishin, ferulic acid, and Z-ligustilide based on the direct comparison of their retention times, UV spectra, and mass spectra with those of the authentic compounds. Furthermore, 31 compounds were tentatively characterized according to their UV spectra, empirical molecular formula, and mass fragmentation pathways as well as their eluted sequence from ODS column reported in the literature [11-14] and acquired in the present experiments.

3.2.1. Fragmentation Characteristic of Reference Compounds. In the present HPLC and MS conditions, characteristic MS adduct ions were observed for phenolic glycosides, organic acid, and phthalide derivatives. Phenolic glycosides and organic acids could be well-detected in positive and negative ionization mode and adduct ions such as  $[M+H]^+$ ,  $[M+NH_4]^+$ ,  $[M+Na]^+$ , and  $[2M+Na]^+$  or  $[M-H]^$ and  $[M+HCOO]^-$  were found, whereas phthalides were only detected in positive mode and mainly showed the abundant  $[M+H]^+$ ,  $[M+Na]^+$ , and  $[2M+Na]^+$  ions. The fragmentation characteristic of reference compounds was similar as those described in the literature [11, 14, 15]. For example, gastrodin, the glucoside of *p*-hydroxybenzyl alcohol, mainly showed characteristic product ions at *m/z* 123 and 161 corresponding to the elimination of a molecule of glucose and a molecule of



FIGURE 2: HPLC and TIC of typical TSC sample obtained using an Agilent 6130 Quadrupole LC-MS connected to an Agilent 1200 HPLC system. (a) HPLC (276 nm), (b) (+) TIC, and (c) (-) TIC.

*p*-hydroxybenzyl alcohol from m/z 285 [M-H]<sup>-</sup>, respectively. Parishin B and C, the gastrodin derivatives with citric acid, mainly indicated the fragmentation of the ester glucoside bond and the neutral loss of gastrodin residue (268 Da) corresponding to the ion at m/z 459. The ions at m/z 441, 423, 397, and 379 were also observed, which were related to elimination of H<sub>2</sub>O and CO<sub>2</sub> from the tertiary alcoholic hydroxyl group and the free carboxylic groups produced by breaking of the ester glucoside bond. Phthalides mainly displayed two pathways: side-chain cleavage with loss of alkenes and ring-opening followed by elimination of H<sub>2</sub>O and CO. These series of characteristic ion rules would be beneficial to elucidate the chemical constituents in TSC sample.

3.2.2. Identification of Phenolics Derivatives in TSC Sample. Compounds 1 and 2 gave the same on-line UV spectrum which is in accordance with that of gastrodin. The structure of 2 was identified as gastrodin based on the comparison of retention time, UV spectrum, and characteristic fragment ions with those of authentic compound as well as accurate molecular weight. The molecular weight of 1 was deduced as 448 from the sodium adduct ion at m/z 471 [M+Na]<sup>+</sup> detected in positive mode and deprotonated molecular ion at m/z 447 [M-H]<sup>-</sup> in negative mode, respectively. A prominent neutral loss of 162 Da, corresponding to the loss of hexose, and disaccharide residue ions at m/z 323 were observed in MS<sup>2</sup> of the [M-H]<sup>-</sup> ion at m/z 447. The loss of 124 Da was assigned to *p*-hydroxybenzyl alcohol just like the characteristic loss of gastrodin. Therefore, compound 1 was identified as elatoside, namely, 6'-(*p*-hydroxybenzyl methyl)-gastrabiose, which was previously isolated from the rhizome of *G. elata* [16].

Compounds 4, 5, 6, and 7 gave the adduct ions  $[M+Na]^+$ and  $[M+NH_4]^+$  in positive LC-MS and  $[M-H]^-$  in negative LC-MS experiments as well as UV spectra, which were similar to those of gastrodin derivatives. Compounds 5 and 6 had the same  $[M-H]^-$  ions at m/z 727, which produced the prominent fragment ion at m/z 459 in the MS<sup>2</sup>, due to loss of gastrodin residue (268 Da) as well as other ions at m/z 441, 423, 397, and 379. Combining with retention time and addition of reference substances, 5 and 6 were identified as parishin B and C. Similarly, compound 4 was assigned to parishin E

Identified compounds	Gastrodin	5-HMF	Parishin E/G	Parishin B	Parishin C	3-Butyl-3,6,7-trihydroxy-4,5,6,7	-tetrahydrophthalide ferulic acid	Contracted 1/NI	Senkyunolide J/IN	4,2-Dinyaro-3,1 -ainyaroxy-3 -butviphthalide	4-hydroxyl-3-butylphthalide	unidentified	Senkyunolide D or	4,7-dihydroxy-3-butylidenephthalide	Z-6,7-Epoxyligustilide	Senkyunolide K/G	Senkyunolide F	Senkyunolide A	Butylphthalide	Senkyunolide C	Senkyunolide E	Cnidilide	Ligustilide	Neocnidilide	3-Butylidenephthalide	Riligustilide	Senkyunolide P	3',6,8',3a-Biligustilide	Tokinolide B	Unidentified	Levistolide A	3'Z-3,3'a,8,6'a-Biligustilide	Senkyunolide M	Senkyunolide Q	Unidentified
Chuanxiong	I	I	I	I	I	+	- +		÷	+	+	+	-	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Tianma	+	+	+	+	+	I	+	-	I	I	I	+		I	Ι	I	I	+	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I
$[M + HCOO]^{-}$	331														435	439	435			249	249														
$[2M + Na]^{+}$						507		176	C/4	471								407	403	431	431	411	403	411	399										383
$[M + Na]^+$		149	483	751	751	265	202	010	647	247			245	C <del>1</del> 7	229	231	229	215	213	227	227	217	213	217	211	403	405	403	403	405	403		579	579	405
$[M + NH_4]^+$	304	144	478	746	746														208						206	398	399	398	398	400			301	301	400
$[M + H]^+$		127				243	195		177	225	207	397	112	C77	207	209	207	193	191	205	205	195	191	195	189	381	383	381	381	383	381	381	279	279	383
$[M - H]^{-}$			459	727	727	741	193				205		101	177	205	207	205			203	203														
MM	286	126	460	728	728	747	194	7.0	077	224	206	396		777	206	208	206	192	190	204	204	194	190	194	188	380	382	380	380	382	380	380	278	278	382
UV $\lambda_{\rm max}/\rm{nm}$	221, 276	230, 283	225	221, 272	221, 274	218	220 236 323	210 220 CT	220, 330	280	275	325	020 000	220, 270	230, 310	280	220	220, 240, 325	226, 280	218, 270	210, 285, 330	220, 270, 330	205, 280, 328	220	210, 275, 330	225, 280, 310	276	220, 280	220, 280	230, 279	220, 275	220, 285	220, 280	220, 280	225, 278
ber $t_R/\min$	5.403	7.736	15.579	20.691	22.220	75 080	75 567	10000	670.17	30.667	32.436	34.299	30 63E	CC0.0C	39.502	39.898	41.465	42.332	42.956	43.717	44.147	44.949	45.831	46.394	46.653	47.231	50.042	50.476	50.970	51.065	51.962	52.267	52.693	53.134	53.852
Numl	7	3	4	5	9	ø	) <b>6</b>		10	11	13	14	71	01	17	18	19	20	21	22	23	24	26	27	28	29	30	31	32	33	34	35	36	37	38

. . ć . Ë ŕ -5.1 5 5 A LC ζ 1 1117 3 • 1. R o

6

Gastrodi	4						H - H		Main product ions
		221, 276	471		_	4	447	493	323[M – H-C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ] <sup>-</sup> , 285[M – H-glc] <sup>-</sup> , 179
Gastrodin (286)		220, 269	309			$185[M + Na-C_7H_8O_2]^+$	285	331	$161[M - H - C_7 H_8 O_2]^-,$ 173 $M - H_{-clc}l^{-1}$
5-HMF (126)		230, 283		127		$109[M + H - H_2 O]^+$	125		
Parishin B (728) Parishin C (728)		221, 272 221, 274	751 751			483[M + Na-268]', 215[483-268]' 483[M + Na-268] <sup>+</sup> , 215[483-268] <sup>+</sup>	727 727		459, 441, 423, 397, 379, 217 459, 441, 423, 397, 379, 217
Parishin (996)		221, 271					995		$727[M - H-268]^{-}$
Ferulic acid (194)		220, 236, 323		195		$177[M + H-H_2O]^+,$ $145[177-CH_3OH]^+$ $209[M + H-H,O]^+$			
Senkyunolide J/N (226)		220, 330	249		475	$191[M + H-2H_2O]^+$			
4,5-Dihydro-3,1′ -dihydroxy ·3-butylphthalide (224)		280	247			105[M + H-H <sub>2</sub> O] <sup>+</sup> , 189[M + H-2H <sub>2</sub> O] <sup>+</sup> , 165, 121			
Senkyunolide I/H (224)		276	247			207[M + H-H <sub>2</sub> O] <sup>+</sup> , 189[M + H-2H <sub>2</sub> O] <sup>+</sup> , 161[189-H <sub>2</sub> O] <sup>+</sup> , 133[189-56] <sup>+</sup>			
Unidentified (316)		230, 276, 280	339	317		$299[M + H-H_2O]^+$ , $281[M + H-2H_2O]^+$ , $771[M + H-H_2O_281^+$ , $243$	315		
Z-6,7-Epoxyligustilide (206)		230	229		413	$189[M + Na + H_2O]^+, 171[189 + H_2O]^+$			
Senkyunolide K/G (208)		233, 280	231		439	$191[M + H-H_2O]^+$ , $173[191 - H_2O]^+$ , 149[191-42] <sup>+</sup> , 135[191-56] <sup>+</sup>			
Senkyunolide A (192) 3utylphthalide (190)		280 232, 275	215 213	193 191	407 403	175[M + H-H <sub>2</sub> O] <sup>+</sup> , 147, 119, 105 173[M + H-H <sub>2</sub> O] <sup>+</sup> , 145, 117			
Unidilide (194) E-Ligustilide (190)	23	8, 279, 327 281, 327	217 213	191	403	$173[M + H-H_2O]^+, 130$			
Z-Ligustilide (190)	53	37, 260, 312	213	191	403	$173[M + H-H_2O]^+$ , 145 $[173-28]^+$ 130, 117 105			
3-Butylidenephthalide (188) 23	23	0, 277, 326	211	189		171[M + H-H <sub>2</sub> O] <sup>+</sup> , 153[171-H <sub>2</sub> O] <sup>+</sup>			
Senkyunolide P (382)		278	405	383 383		ZIJ ZMI + INA-190] , 191, 1/2 192[M + H-190] <sup>+</sup>			
3',6,8',3a-Biligustilide (380)		278, 363	403	381		$213[2M + Na-190]^+$ , $191[M + H-190]^+$ ,			
Tokinolide B (380)		278	403	381		$213[2M + Na-190]^+$ , $191[M + H-190]^+$			
Unidentified (382)		230, 279	405	383		$193[M + H-190]^+$			
Levistolide A (380)		276	403	381		213[2M + Na-190] <sup>+</sup> , 191[M + H-190] <sup>+</sup> , 145, 117			
Senkyunolide O (380)		278	403	381		173[191-H <sub>2</sub> O] <sup>+</sup> , 191[M + H-190] <sup>+</sup> , 145, 117			
Senkyunolide M (278)		279	301	279		$245[M + Na-56]^+, 189, 171$			
Senkyunolide Q (278)		278	301	279		245[M + Na-56] <sup>+</sup> , 189, 171			
Uniaenunea (382)		2.25, 278	405	383					
<b>4 4 5 6 7 7 7 7 7 7 7 7 7 7</b>		Senkyunolide J/N (226) 4,5-Dihydro-3,1'-dihydroxy -3-butylphthalide (224) Senkyunolide I/H (224) Unidentified (316) Z-6,7-Epoxyligustilide (206) Senkyunolide K/G (208) Senkyunolide K/G (208) Senkyunolide K/G (208) Cridilide (194) E-Ligustilide (190) Cridilide (190) Z-Ligustilide (190) Senkyunolide P (380) Y,6,8',3a-Biligustilide (380) Tokinolide P (382) 3',6,8',3a-Biligustilide (380) Tokinolide B (380) Unidentified (382) Senkyunolide A (380) Senkyunolide A (380) Senkyunolide A (278) Senkyunolide Q (278) Unidentified (382)	Senkyunolide J/N (226)220, 330 $4,5$ -Dihydror $3,1'$ -dihydroxy $280$ $-3$ -butylphthalide (224) $280$ $-3$ -butylphthalide (224) $280$ $2$ -senkyunolide I/H (224) $230, 276, 280$ $2$ - $6,7$ -Epoxyligustilide (206) $230, 276, 280$ $2$ - $6,7$ -Epoxyligustilide (206) $233, 280$ $2$ - $6,7$ -Epoxyligustilide (190) $233, 280$ $2$ - $6,7$ -Epoxyligustilide (190) $233, 280$ $2$ - $6,7$ -Epoxyligustilide (190) $233, 275$ $2$ -Ligustilide (190) $233, 275$ $3, 6, 8', 3a$ -Biligustilide (188) $230, 277$ $3, 6, 8', 3a$ -Biligustilide (380) $278$ $3', 6, 8', 3a$ -Biligustilide (382) $276$ $3', 6, 8', 3a$ -Biligustilide (382) $276$ $3, $	Senkyunolide J/N (226) $220, 330$ $249$ $4,5-$ Dihydro- $3,1'$ -dihydroxy $280$ $247$ $-3$ -butylphthalide (224) $280$ $247$ $-3$ -butylphthalide (224) $276$ $247$ Senkyunolide I/H (224) $276$ $247$ Unidentified (316) $230, 276, 280$ $339$ $Z-6,7-$ Epoxyligustilide (208) $233, 280$ $231$ Senkyunolide K/G (208) $233, 280$ $231$ Senkyunolide K/G (208) $233, 275, 230$ $215$ Butylphthalide (190) $233, 275, 327, 213$ $213$ Senkyunolide (190) $233, 277, 326$ $211$ Butylphthalide (190) $237, 260, 312$ $213$ Senkyunolide R (380) $277, 326$ $211$ Butylidenephthalide (188) $230, 277, 326$ $213$ Senkyunolide P (382) $230, 277, 326$ $403$ Senkyunolide B (380) $278, 363$ $403$ Tokinolide B (380) $278, 363$ $403$ Tokinolide B (380) $278, 363$ $403$ Senkyunolide A (380) $278, 363$ $403$ Senkyunolide M (278) $279$ $279$ $403$ Senkyunolide M (278) $279$ $279$ $403$ Senkyunolide M (278) $279$ $279$ $301$ Senkyunolide Q (278) $279$ $279$ $301$ Senkyunolide Q (278) $279$ $279$ $301$ Senkyunolide Q (278) $279$ $279$ $279$ Senkyunolide Q (278) $279$ $279$ $279$ Senkyunolide Q (278) $279$ $279$ $279$ <td>Senkyunolide J/N (226)<math>220, 330</math><math>249</math><math>4,5</math>-Dihydror <math>3,1'</math>-dihydroxy<math>280</math><math>247</math><math>-3</math>-butylphthalide (224)<math>280</math><math>247</math><math>5</math>-butylphthalide (224)<math>276</math><math>247</math>Senkyunolide I/H (224)<math>276</math><math>247</math>Unidentified (316)<math>230, 276, 280</math><math>339</math><math>7-6,7</math>-Epoxyligustilide (206)<math>230, 276, 280</math><math>231</math><math>2-6,7</math>-Epoxyligustilide (206)<math>233, 280</math><math>231</math><math>2-6,7</math>-Epoxyligustilide (190)<math>233, 280</math><math>231</math><math>2-6,7</math>-Epoxyligustilide (190)<math>233, 275, 327</math><math>217</math><math>21-1igustilide (190)</math><math>233, 277, 326</math><math>211</math><math>8utylidenephthalide (190)</math><math>238, 279, 327</math><math>211</math><math>8utylidenephthalide (190)</math><math>233, 277, 326</math><math>211</math><math>8utylidenephthalide (190)</math><math>233, 277, 326</math><math>211</math><math>3-Ligustilide (380)</math><math>233, 277, 326</math><math>213</math><math>3-Ligustilide (380)</math><math>230, 277, 326</math><math>213</math><math>3-Ligustilide (380)</math><math>233, 277, 326</math><math>213</math><math>3-Ligustilide (380)</math><math>233, 277, 326</math><math>213</math><math>3-Ligustilide (380)</math><math>233, 277, 326</math><math>403</math><math>3-Ligustilide (380)</math><math>230, 277, 326</math><math>403</math><math>3-Ligustil</math></td> <td>Senkynnolide //N (226)<math>220, 330</math><math>249</math><math>475</math><math>4,5</math>-Dihydro-<math>31'</math>-dihydroxy<math>280</math><math>247</math><math>475</math><math>-3</math>-butyfphthalide (224)<math>280</math><math>247</math><math>413</math><math>5</math>-mkyunolide 1/H (224)<math>276</math><math>247</math><math>413</math><math>5</math>-mkyunolide (216)<math>230, 276, 280</math><math>339</math><math>317</math><math>Z</math>-<math>6,7</math>-Epoxyligustilide (206)<math>230, 276, 280</math><math>339</math><math>407</math><math>2</math>-<math>6,7</math>-Epoxyligustilide (206)<math>233, 280</math><math>229</math><math>403</math><math>5</math>-<math>6,7</math>-Epoxyligustilide (190)<math>233, 280</math><math>215</math><math>191</math><math>403</math><math>5</math>-mkyunolide K/G (208)<math>233, 279, 327</math><math>213</math><math>191</math><math>403</math><math>5</math>-mkyunolide (190)<math>238, 279, 327</math><math>213</math><math>191</math><math>403</math><math>5</math>-<math>6,8',3a</math>-Biligustilide (190)<math>233, 277, 326</math><math>211</math><math>191</math><math>403</math><math>7,6,8',3a</math>-Biligustilide (190)<math>237, 260, 312</math><math>213</math><math>191</math><math>403</math><math>7,6,8',3a</math>-Biligustilide (188)<math>230, 277, 365</math><math>403</math><math>381</math><math>7,6,8',3a</math>-Biligustilide (380)<math>278, 363</math><math>403</math><math>381</math><math>7,6,8',3a</math>-Biligustilide (380)<math>278, 363</math><math>403</math><td>Senkynnolide //N (256) 220, 330 249 475 <math>200[M + H + H_2O]^4</math>, <math>180[M + H - 2H_2O_3]^4</math>   4,5-Dihydro-3,1' dihydroxy 280 247 <math>207[M + H + H_2O]^4</math>, <math>189[M + H - 2H_2O_1]^4</math>, <math>180[M + H - 2H_2O]^4</math>, <math>180[M + H - 2H_2O]^4</math>, <math>360[M + H - 2H_2O_1]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>180[M + H - 2H_2O]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>180[M + H - 2H_2O]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>208[M + H - 2H_2O]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>208[M + H - 2H_2O]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>208[M + H - 2H_2O]^4</math>, <math>200[M + H + H_2O]^4</math>, <math>200[M + H + H_2O]^4</math>, <math>200[M + H - H_2O]^4</math>, <math>100[M + H - H_2O]^4</math>, <math>100[M</math></td><td><math display="block"> \begin{array}{llllllllllllllllllllllllllllllllllll</math></td><td>Senkynnolide / N (226)220, 330249475<math>200(M + H+3)(1^+, 124, 0)^+, 130(M + </math></td></td>	Senkyunolide J/N (226) $220, 330$ $249$ $4,5$ -Dihydror $3,1'$ -dihydroxy $280$ $247$ $-3$ -butylphthalide (224) $280$ $247$ $5$ -butylphthalide (224) $276$ $247$ Senkyunolide I/H (224) $276$ $247$ Unidentified (316) $230, 276, 280$ $339$ $7-6,7$ -Epoxyligustilide (206) $230, 276, 280$ $231$ $2-6,7$ -Epoxyligustilide (206) $233, 280$ $231$ $2-6,7$ -Epoxyligustilide (190) $233, 280$ $231$ $2-6,7$ -Epoxyligustilide (190) $233, 275, 327$ $217$ $21-1igustilide (190)$ $233, 277, 326$ $211$ $8utylidenephthalide (190)$ $238, 279, 327$ $211$ $8utylidenephthalide (190)$ $233, 277, 326$ $211$ $8utylidenephthalide (190)$ $233, 277, 326$ $211$ $3-Ligustilide (380)$ $233, 277, 326$ $213$ $3-Ligustilide (380)$ $230, 277, 326$ $213$ $3-Ligustilide (380)$ $233, 277, 326$ $213$ $3-Ligustilide (380)$ $233, 277, 326$ $213$ $3-Ligustilide (380)$ $233, 277, 326$ $403$ $3-Ligustilide (380)$ $230, 277, 326$ $403$ $3-Ligustil$	Senkynnolide //N (226) $220, 330$ $249$ $475$ $4,5$ -Dihydro- $31'$ -dihydroxy $280$ $247$ $475$ $-3$ -butyfphthalide (224) $280$ $247$ $413$ $5$ -mkyunolide 1/H (224) $276$ $247$ $413$ $5$ -mkyunolide (216) $230, 276, 280$ $339$ $317$ $Z$ - $6,7$ -Epoxyligustilide (206) $230, 276, 280$ $339$ $407$ $2$ - $6,7$ -Epoxyligustilide (206) $233, 280$ $229$ $403$ $5$ - $6,7$ -Epoxyligustilide (190) $233, 280$ $215$ $191$ $403$ $5$ -mkyunolide K/G (208) $233, 279, 327$ $213$ $191$ $403$ $5$ -mkyunolide (190) $238, 279, 327$ $213$ $191$ $403$ $5$ - $6,8',3a$ -Biligustilide (190) $233, 277, 326$ $211$ $191$ $403$ $7,6,8',3a$ -Biligustilide (190) $237, 260, 312$ $213$ $191$ $403$ $7,6,8',3a$ -Biligustilide (188) $230, 277, 365$ $403$ $381$ $7,6,8',3a$ -Biligustilide (380) $278, 363$ $403$ <td>Senkynnolide //N (256) 220, 330 249 475 <math>200[M + H + H_2O]^4</math>, <math>180[M + H - 2H_2O_3]^4</math>   4,5-Dihydro-3,1' dihydroxy 280 247 <math>207[M + H + H_2O]^4</math>, <math>189[M + H - 2H_2O_1]^4</math>, <math>180[M + H - 2H_2O]^4</math>, <math>180[M + H - 2H_2O]^4</math>, <math>360[M + H - 2H_2O_1]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>180[M + H - 2H_2O]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>180[M + H - 2H_2O]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>208[M + H - 2H_2O]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>208[M + H - 2H_2O]^4</math>, <math>207[M + H + H_2O]^4</math>, <math>208[M + H - 2H_2O]^4</math>, <math>200[M + H + H_2O]^4</math>, <math>200[M + H + H_2O]^4</math>, <math>200[M + H - H_2O]^4</math>, <math>100[M + H - H_2O]^4</math>, <math>100[M</math></td> <td><math display="block"> \begin{array}{llllllllllllllllllllllllllllllllllll</math></td> <td>Senkynnolide / N (226)220, 330249475<math>200(M + H+3)(1^+, 124, 0)^+, 130(M + </math></td>	Senkynnolide //N (256) 220, 330 249 475 $200[M + H + H_2O]^4$ , $180[M + H - 2H_2O_3]^4$ 4,5-Dihydro-3,1' dihydroxy 280 247 $207[M + H + H_2O]^4$ , $189[M + H - 2H_2O_1]^4$ , $180[M + H - 2H_2O]^4$ , $180[M + H - 2H_2O]^4$ , $360[M + H - 2H_2O_1]^4$ , $207[M + H + H_2O]^4$ , $180[M + H - 2H_2O]^4$ , $207[M + H + H_2O]^4$ , $180[M + H - 2H_2O]^4$ , $207[M + H + H_2O]^4$ , $208[M + H - 2H_2O]^4$ , $207[M + H + H_2O]^4$ , $208[M + H - 2H_2O]^4$ , $207[M + H + H_2O]^4$ , $208[M + H - 2H_2O]^4$ , $200[M + H + H_2O]^4$ , $200[M + H + H_2O]^4$ , $200[M + H - H_2O]^4$ , $100[M + H - H_2O]^4$ , $100[M$	$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Senkynnolide / N (226)220, 330249475 $200(M + H+3)(1^+, 124, 0)^+, 130(M + $

Evidence-Based Complementary and Alternative Medicine

Number	t <sub>n</sub> /min	Identified compounds	Formula	Mea. mass/ <i>m/z</i>	Calc. mass/m/z	Error/ppm	Other precursor ions	Main product ions
3	7.6	5-HMF (126)	C <sub>6</sub> H <sub>6</sub> O <sub>3</sub>	$127.0384[M + H]^{+}$	127.0390[M + H] <sup>+</sup>	-4.72	$149.0240[M + Na]^+$	e
5	19.8	Parishin B (728)	$C_{32}H_{40}O_{19}$	$727.2123[M - H]^{-1}$	$727.2091[M - H]^{-1}$	4.40		
9	21.5	Parishin C (728)	$C_{32}H_{40}O_{19}$	$727.2132[M - H]^{-}$	$727.2091[M - H]^{-}$	5.64		
œ	24.5	3-Butyl-3,6,7-trihydroxy-4,5,6,7- tetrahvdrophthalide	C.,H.,O.	241.1090[M – H1 <sup>–</sup>	241.1081[M – H] <sup>–</sup>	3.72		223.0885[M - H-H <sub>2</sub> O] <sup>-</sup> , 197.1142,
		(242)	0 07 77					1/9.110/, 141.0930, 123.0854
0	753	Femilic acid (194)	С. Н. О.	243.1220[M + H] <sup>+</sup> 195.0649[M + H] <sup>+</sup>	243.1227[M + H] <sup>+</sup> 195.0652[M + H] <sup>+</sup>	2.88 -1 54	265.1060[M + Na] <sup>+</sup> 2170458[M + Na1 <sup>+</sup>	
Ş								$209.1177[M + H-H, O]^+$ ,
10	27.0	Senkyunolide J/N (226)	$C_{12}H_{18}O_4$	227.1259[M + H]	227.1278[M + H]	-3.37	249.1082[M + Na]	$191.1026[M + H-2H_2O]^{+}$
п	30.3	4,5-Dihydro-3,1′-dihydroxy-3- butylphthalide	$C_{12}H_{16}O_4$	225.1105[M + H] <sup>+</sup>	225.1121[M + H] <sup>+</sup>	-7.11		1
17	315	(224) Sentrumolide I/H (224)	C I U	335 1105[M ± H] <sup>+</sup>	225 1131[M ± H1 <sup>+</sup>	117-		
1	0.10							$299.1378[M + H-H_{3}O]^{+}$ ,
15	37.8	Unidentified (316)	$C_{18}H_{20}O_5$	317.1380[M + H] <sup>+</sup>	317.1384[M + H] <sup>+</sup>	-1.26	339.1210[M + Na] <sup>+</sup>	$271.1343[M + H-H_2O-28]^+$
16	37.8	4,7-Dihydroxy-3-butylidenephthalide or	$C_{12}H_{14}O_4$	$223.0986[M + H]^{+}$	$223.0965[M + H]^{+}$	9.41	$245.0774[M + Na]^{+}$	8
17	20.7	7 6 7 Enovyliance D (222)		2071000[M - 111 <sup>+</sup>	י אוזאוטודטע	3 66	$330.0834$ [M $\pm $ No1 <sup>+</sup>	180 0856[M ± H H Ol <sup>+</sup> 133 0318
18	30.7	z-0,/-т.рохудизицие (200) Senkvinolide K/G (208)	C12 H 14 O3	1001167[M + H] <sup>+</sup>	207.10101/17 + H] <sup>+</sup>	00.0 -7 30	222.0024[M1 + Na] 231.0974[M + Na] <sup>+</sup>	101 1001 [M + H-H2O] , 100 0010 101 1001 [M + H-H2O] 119 0810
6I	40.6	Senkvunolide F (206)	C12H16O3 C1,H1,O3	$2071009[M + H]^+$	$207.1016[M + H]^+$	3.38	$229.0815[M + Na]^{+}$	$189.0911[M + H-H,O]^{+}$ , 161.0959
			C - HI 7I -	$205.0874[M - H]^{-1}$	$205.0870[M - H]^{-1}$	1.95	$411.1821[2M - H]^{-1}$	$161.0976[M - H-44]^{-}, 106.0421$
20	41.4	Senkyunolide A (192)	$C_{12}H_{16}O_2$	193.1219[M + H] <sup>+</sup>	193.1223[M + H] <sup>+</sup>	-2.07	$215.1027[M + Na]^+$ , $4072196[2M + Na]^+$	$175.1119[M + H-H_2O]^+$ , 147.1155, 105.0718
21	42.1	Butylphthalide (190)	$C_{12}H_{14}O_{2}$	$191.1061[M + H]^+$	191.1067[M + H] <sup>+</sup>	-3.14	$213.0872[M + Na]^+$ $403.1888[2M + Na]^+$	173.0989[M + H-H <sub>2</sub> O] <sup>+</sup> , 145.1049[M + H-H, O-28] <sup>+</sup>
22	42.9	Senkyunolide C (204)	$C_{12}H_{12}O_3$	$205.0847[M + H]^{+}$	$205.0859[M + H]^{+}$	-5.85	227.0685[M + Na] <sup>+</sup> , 431.1431[2M + Na] <sup>+</sup>	$187.0763[M + H - H_2^{\circ}O]^{+},$ 169.0757[M + H - 2H_2O]^{+},
23	43.4	Senkyunolide E (204)	$C_{12}H_{12}O_3$	$205.0843[M + H]^{+}$	$205.0859[M + H]^{+}$	-7.80	$227.0663[M + Na]^+$	[07-60]66001#T
24	44.1	Cnidilide (194)	C1, H18O,	195.1372[M + H] <sup>+</sup>	195.1380[M + H] <sup>+</sup>	-4.10	217.1185[M + Na] <sup>+</sup>	$177.1323[M + H-H_2O]^+$ ,
25	441	E-Lionstilide (190)	CHO.	191 1061[M + H] <sup>+</sup>	191 1067[M + H] <sup>+</sup>	-3 14	213 0871[M + Nal <sup>+</sup>	$149.1340[M + H-H_2O-28]$
ì	111.1		~12 ± 14 ~ 2			1110	213.0859[M + Na] <sup>+</sup>	$1730984[M + H-H_{\circ}O]^{+}$
26	45.2	Z-Ligustilide (190)	$C_{12}H_{14}O_2$	$191.1056[M + H]^{+}$	$191.1067[M + H]^{+}$	-5.76	$403.1901[2M + Na]^+$	$145.099[M + H - H_2O-28]^+$ , 117.0690
27	45.5	Neocnidilide (194)	$\rm C_{12}H_{18}O_2$	$195.1372[M + H]^{+}$	$195.1380[M + H]^{+}$	-4.10	217.1179[M + Na] <sup>+</sup>	$177.1323[M + H - H_2 O]$ , 149.1306[M + H - H_2 O - 28] <sup>+</sup> , 121.0998
28	45.8	3-Butylidenephthalide (188)	$C_{12}H_{12}O_2$	189.0907[M + H] <sup>+</sup>	189.0910[M + H] <sup>+</sup>	-1.59	$211.0720[M + Na]^+$	171.0817[M + H-H <sub>2</sub> O] <sup>+</sup> , 153.0800[M + H-H <sub>2</sub> O-H <sub>2</sub> O] <sup>+</sup> , 143.0882[M + H-H,O-28] <sup>+</sup> , 129.0724
29	46.2	Riligustilide (380)	$C_{24}H_{28}O_4$	$381.2058[M + H]^{+}$	$381.2060[M + H]^{+}$	-0.52	403.1872[M + Na] <sup>+</sup> ,	
30	48.9	Senkyunolide P (382)		$383.2220[M + H]^{+}$	383.2217[M + H] <sup>+</sup>		$405.2031[M + Na]^+$	$193.1212[M/2 + H]^+$
31	49.2	3′,6,8′,3a-Biligustilide (380)	$C_{24}H_{28}O_4$	$381.2058[M + H]^+$	$381.2060[M + H]^{+}$	-0.52	403.1885[M + Na] <sup>+</sup> ,	
32	49.8	Tokinolide B (380)	$\mathrm{C}_{24}\mathrm{H}_{28}\mathrm{O}_4$	381.2037[M + H] <sup>+</sup>	$381.2060[M + H]^{+}$	-6.03	$403.1878[M + Na]^+$ ,	
33	49.9	Unidentified (382)		$383.2220[M + H]^{+}$	383.2217[M + H] <sup>+</sup>		$405.2040[M + Na]^+$	$193.1214[M/2 + H]^+$
34	50.3	Levistolide A (380)	$C_{24}H_{28}O_4$	$381.2064[M + H]^{+}$	$381.2060[M + H]^{+}$	1.05	403.1887[M + Na] <sup>+</sup> ,	
35	50.8	Senkvunolide O (380)	C.,H.,O,	381.2061[M + H] <sup>+</sup>	381.2060[M + H] <sup>+</sup>	0.26	$403.1879[M + Na]^+$ ,	191.1051[M/2 + H] <sup>+</sup>
			F _ 07 _ F7 _				191.1057 3011402[M + Nal <sup>+</sup>	
36	51.4	Senkyunolide M (278)		279.1582[M + H] <sup>+</sup>			$579.2952[2M + Na]^+$	
37	52.0	Senkyunolide Q (278)		$279.1596[M + H]^+$			$301.1381[M + Na]^{T}$ , 579 2.952[2M + Na] <sup>+</sup>	
38	52.7	Unidentified (382)		383.2217[M + H] <sup>+</sup>	383.2217[M + H] <sup>+</sup>	0.00	$405.2008[M + Na]^+$	$365.2115, 347.1905, 193.1201[M/2 + H]^{+}$

TABLE 3: Retention time  $(t_{a})$  and MS data obtained by LC-DAD-ESI-IT-TOF/MS of the identified compounds in the sample of Tianshu Capsule.

8

or its positional isomer parishin G with identical molecular mass of 460 [17]. Compound 7 had the molecular mass of 996 and exhibited consecutive loss of gastrodin residue (268 Da), and, therefore, it was identified as parishin, a conjugate of one citric acid and three gastrodins.

3.2.3. Identification of Phthalide Derivatives in TSC Sample. The molecular formula of compound **8**, detected from individual herb *Chuanxiong rhizoma*, was calculated as  $C_{12}H_{18}O_5$  by  $[M+H]^+$  ion at m/z 243.1220 and  $[M-H]^-$  ion at m/z 241.1090 in its LC-IT-TOF/MS experiment. It had the same molecular weight of 242 as those of known compounds, senkyunolide L and 3-butyl-3,6,7-trihydroxy-4,5,6,7-tetrahydrophthalide, present in *Chuanxiong rhizoma*; however, compound **8** could not be senkyunolide L ( $C_{12}H_{15}CIO_3$ ) because both had the different element composition [18]. The fragmentation ion of **8** at m/z 197.1142, which was derived from a retro-Diels-Alder cleavage of the [M-H-H<sub>2</sub>O]<sup>-</sup> ion at m/z 223.0885, suggested that the structure of **8** was proposed as 3-butyl-3,6,7-trihydroxy-4,5,6,7-tetrahydrophthalide.

Compound 10 displayed  $[M+H]^+$  ion at m/z 227.1259, suggesting the molecular formula of C<sub>12</sub>H<sub>18</sub>O<sub>4</sub>. The fragment ions at m/z 209 and 191 in the MS<sup>2</sup>, indicating consecutive loss of H<sub>2</sub>O, supported that 10 was a dihydroxylated derivative of ligustilide. UV and MS data of 10 were in accordance with those of senkyunolide J and senkyunolide N, but the stereochemistry information of two hydroxy groups could not be provided. Thus, 10 was tentatively assigned as one of senkyunolide J and senkyunolide N. Compounds 11 and 12 gave the same  $[M-H]^-$  ions at m/z 224 and their molecular formula was established as C<sub>12</sub>H<sub>18</sub>O<sub>4</sub> according to the  $[M+H]^+$  ion at *m/z* 225.1105. However, both constituents had different fragmentation rules. The MS<sup>2</sup> of 11 displayed the fragment ions at m/z 207, 189 and the characteristic ion at m/z 165, which were similar to those of 4,5-dihydro-3,1'dihydroxy-3-butylphthalide [15], whereas 12 showed elimination of two H<sub>2</sub>O followed by side-chain cleavage. Therefore, 11 was deduced as 4,5-dihydro-3,1'-dihydroxy-3-butylphthalide and 12 could be one of senkyunolide I and senkyunolide H [14, 15].

Compounds 13, 17, and 19 have the same molecular formula of  $C_{12}H_{14}O_3$  and were tentatively characterized as 4-hydroxy-3-butylphthalide, *Z*-6,7-epoxyligustilide, and senkyunolide F. Compared with monohydroxy phthalide derivatives 13 and 19, the instable structure of 17 resulted in the ion at m/z 189 as base peak observed in MS<sup>1</sup>, suggesting loss of H<sub>2</sub>O from the [M-H]<sup>-</sup> ion at m/z 207. Senkyunolide A 20 and *Z*-ligustilide 26 as main constituents were identified and butylphthalide 21, senkyunolide C 22, senkyunolide E 23, *E*-ligustilide 24, and 3-butylidenephthalide 28 were characterized as minor constituents. For the compounds 20, 21, 24, and 26, the neutral loss of CO (28 Da) and sidechain cleavage (56 Da) from [M+H-H<sub>2</sub>O]<sup>+</sup> were the common fragmentation rules.

Compound **16**  $(C_{12}H_{14}O_3)$  was tentatively proposed to 4,7-dihydroxy-3-butylidenephthalide or senkyunolide D. Compound **18** was assigned as senkyunolide K or senkyunolide G. These compounds and their isomers could not be differentiated by available MS data.

Five dimeric ligustilides 29, 31, 32, 34, and 35, which produced the protonated ion  $[M+H]^+$  at m/z 381, were detected in extracted ion chromatograms. They showed the base peak at m/z 403 [M+Na]<sup>+</sup> in MS<sup>1</sup> and the fragment ion at m/z 191 [M+H-190]<sup>+</sup> as base peak in MS<sup>2</sup> by the loss of a RDA fragment (145 Da) followed by the loss of H<sub>2</sub>O and HCOOH (46 Da). Comprehensively considering the information described in the literature [14], they were tentatively identified as riligustilide, 3',6,8',3a-biligustilide, tokinolide B, levistolide A, and senkyunolide O, respectively. Three compounds, indicating the protonated ion [M+H]<sup>+</sup> at m/z 383, were detected in extracted ion chromatograms; however, only senkyunolide P was previously reported in Chuanxiong Rhizoma. Thus, compound 30 was tentatively characterized as senkyunolide P and the other compounds (33 and 38) were still indefinite based on the available information.

In the modernization of TCM, chemical profiling is always the first task. It is of importance for development of the suitable quality standard and control strategy, study of pharmacokinetics, and interpretation of therapeutic character of TCM [19, 20]. As a marketed product in China, the quality control system of TSC is still to be improved and its pharmacokinetics and action mechanism are not completely clear. Usually, gastrodin, ferulic acid, and 6,7dihydroxyligustilide are selected as marker compounds for the quality control or the pharmacokinetic study of Tianshu Capsule [1, 21, 22]. The present investigation provides more chemical information for the selection of the marker compounds and the improvement of quality control. It also tells the pharmacokinetic scientists and ethnopharmacologists which compounds in TSC samples are worth further evaluation. In addition to gastrodin and ferulic acid, more efforts should be made to the group of phthalide derivatives such as major constituents, senkyunolide I/H 12, 4-hydroxy-3-butylphthalide 13, senkyunolide A 20, and Z-ligustilide 26 as well as their dimers. Additionally, it is worth noting that 5-HMF 3, a potent toxic compound, was found as main peak in the chemical profile of TSC samples. This compound originated from the crude material Gastrodiae rhizoma and its content in TSC samples was up to 2.67 mg·g<sup>-1</sup> [23]. If it is necessary to develop its limit standard in TSC product or not, more study are expected. Also, ligustrazine is not detected in TSC sample, even in the extracted ion chromatogram, which could result from its very low amount in crude herbal material (about 0.01~0.02%), although, actually, it is often considered as one of active components in Chuanxiong rhizoma.

#### 4. Conclusions

In this study, HPLC analysis was employed to find out the common chromatographic peak in various batches of TSC samples. The contribution of the characteristic peaks from individual herbs to the whole chromatographic profile was discussed based on comparative HPLC and LC-MS analyses. A total of 38 constituents were identified based on the comparison of retention time and UV spectra with authentic compounds as well as by summarized MS fragmentation rules and matching empirical molecular formula with those of published components. The present investigation provided the good basis for monitoring the manufacturing processes and improving quality control of TSC products.

#### **Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

#### Acknowledgments

This research work was supported by China Postdoctoral Science Foundation (2012M510731) and State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process (SKL2010M0204). Meanwhile great thanks are due to Dr. Feng Ji from Shimadzu (China) Co., Ltd., Beijing Office, for measuring the LC-DAD-ESI-IT-TOF/MS experiments.

#### References

- [1] Chinese Pharmacopoeia Commission, *Chinese Pharmacopoeia*, vol. 1, China Medical Science Press, Beijing, China, 2010.
- [2] W. Xia, M. J. Zhu, Z. Zhang et al., "Effect of Tianshu capsule in treatment of migraine: a meta-analysis of randomized control trials," *Journal of Traditional Chinese Medicine*, vol. 33, no. 1, pp. 9–14, 2013.
- [3] L. Wang, J. M. Zhang, Y. L. Hong, Y. Feng, M. W. Chen, and Y. T. Wang, "Phytochemical and pharmacological review of Da Chuanxiong formula: a famous herb pair composed of Chuanxiong Rhizoma and Gastrodiae Rhizoma for headache," *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 425369, 16 pages, 2013.
- [4] S. M. Ni, D. W. Qian, E. X. Shang, J. A. Duan, J. M. Guo, and Y. P. Tang, "Analysis of Chemical composition of Da chuanxiong Fang by ultra performance liquid chromatography-electrospray ionization quadrupole time of flight/mass spectrometry," *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 16, no. 1, pp. 40–45, 2010.
- [5] L. Shen, X. Lin, S. Liang et al., "Characterization on central ingredients of active components in dachuanxiong fang based on HPLC-DAD-MSn," *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 18, no. 7, pp. 128–134, 2012.
- [6] Y. F. Wei, X. Lin, N. Zhang, and Y. Feng, "UPLC-MS analysis of constituents of *Dachuanxiong Fang* active parts absorbed into blood," *Zhongguo Zhongyao Zazhi*, vol. 36, no. 9, pp. 1245–1248, 2011.
- [7] Y. Wei, N. Zhang, X. Lin, and Y. Feng, "Release characteristics in vitro and pharmacokinetics of *Da Chuanxiong Fang* multiunit drug delivery system in rats," *Acta Pharmaceutica Sinica*, vol. 46, no. 9, pp. 1150–1155, 2011.
- [8] X. L. Zhang, L. F. Liu, L. Y. Zhu et al., "A high performance liquid chromatography fingerprinting and ultra high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry chemical profiling approach to rapidly find characteristic chemical markers for quality evaluation of dispensing granules, a case study on Chuanxiong Rhizoma," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 88, pp. 391–400, 2014.

- [9] X. Z. Zhang, H. B. Xiao, Q. Xu, X. L. Li, J. N. Wang, and X. M. Liang, "Characterization of phthalides in Ligusticum chuanxiong by liquid chromatographic-atmospheric pressure chemical ionization-mass spectrometry," *Journal of Chromatographic Science*, vol. 41, no. 8, pp. 428–433, 2003.
- [10] S. Li, R. Yan, Y. Tam, and G. Lin, "Post-harvest alteration of the main chemical ingredients in *Ligusticum chuanxiong* HORT. (Rhizoma Chuanxiong)," *Chemical and Pharmaceutical Bulletin*, vol. 55, no. 1, pp. 140–144, 2007.
- [11] L. Wang, H. B. Xiao, X. M. Liang, and L. Wei, "Identification of phenolics and nucleoside derivatives in *Gastrodia elata* by HPLC-UV-MS," *Journal of Separation Science*, vol. 30, no. 10, pp. 1488–1495, 2007.
- [12] T. Yi, K. S. Leung, G. H. Lu, and H. Zhang, "Comparative analysis of *Ligusticum chuanxiong* and related umbelliferous medicinal plants by high performance liquid chromatographyelectrospray ionization mass spectrometry," *Planta Medica*, vol. 73, no. 4, pp. 392–398, 2007.
- [13] R. Yan, S. L. Li, H. S. Chung, Y. Tam, and G. Lin, "Simultaneous quantification of 12 bioactive components of *Ligusticum chuanxiong* Hort. by high-performance liquid chromatography," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 37, no. 1, pp. 87–95, 2005.
- [14] T. Yi, K. S. Leung, G. H. Lu, K. Chan, and H. Zhang, "Simultaneous qualitative and quantitative analyses of the major constituents in the rhizome of Ligusticum chuanxiong using HPLC-DAD-MS," *Chemical and Pharmaceutical Bulletin*, vol. 54, no. 2, pp. 255–259, 2006.
- [15] Q. Wu and X. W. Yang, "GC-MS analysis of essential oil from rhizomes of *Ligusticum chuanxiong* cultivated in GAP Base for Chinese Medicinal Materials of China," *China Journal of Chinese Materia Medica*, vol. 33, no. 3, pp. 276–280, 2008.
- [16] L. Ning, Studies on the constituents of Gastrodia elata and three medicinal plants belongs to Curculigo [Doctoral thesis], Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China, 2004.
- [17] L. Wang, H. Xiao, L. Yang, and Z. T. Wang, "Two new phenolic glycosides from the rhizome of *Gastrodia elata*," *Journal of Asian Natural Products Research*, vol. 14, no. 5, pp. 457–462, 2012.
- [18] M. Kobayashi and H. Mitsuhashi, "Studies on the constituents of umbelliferea plants X VII structure of three new ligustilide derivatives from *Ligusticum wallichii*," *Chemical & Pharmaceutical Bulletin*, vol. 35, no. 12, pp. 4789–4792, 1987.
- [19] Z. Q. Shi, D. F. Song, R. Q. Li et al., "Identification of effective combinatorial markers for quality standardization of herbal medicines," *Journal of Chromatography A*, vol. 1345, pp. 78–85, 2014.
- [20] Z. Hu, J. Yang, C. Cheng et al., "Combinatorial metabolism notably affects human systemic exposure to ginsenosides from orally administered extract of *Panax notoginseng* roots (Sanqi)," *Drug Metabolism and Disposition*, vol. 41, no. 7, pp. 1457–1469, 2013.
- [21] H. F. Zhang, X. H. Chen, Y. S. Huo, and K. S. Bi, "RP-HPLC simultaneous determination of the contents of gastrodin , ferulic acid and 6,7-dihydroxyligustilide in Tianshu capsules under a changed UV wavelengths," *Journal of Shenyang Pharmaceutical University*, vol. 29, no. 6, pp. 443–447, 2012.
- [22] H. Zhang, L. Sun, X. Chen, Y. Huo, B. Yan, and K. Bi, "Simultaneous quantification of 6,7-di-hydroxyligustilide and gastrodin in rat plasma by LC-MS: application to pharmacokinetic study of Tianshu capsule," *Latin American Journal of Pharmacy*, vol. 31, no. 1, pp. 112–119, 2012.

Evidence-Based Complementary and Alternative Medicine

[23] J. J. Liang, H. M. Gao, L. M. Chen et al., "Simultaneous determination of three constituents in Tiansu Capsule by HPLC," *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 19, no. 17, pp. 81–84, 2013.